CO2022010743A2 - Sars-cov-2 desoptimizados y métodos y usos de los mismos - Google Patents

Sars-cov-2 desoptimizados y métodos y usos de los mismos

Info

Publication number
CO2022010743A2
CO2022010743A2 CONC2022/0010743A CO2022010743A CO2022010743A2 CO 2022010743 A2 CO2022010743 A2 CO 2022010743A2 CO 2022010743 A CO2022010743 A CO 2022010743A CO 2022010743 A2 CO2022010743 A2 CO 2022010743A2
Authority
CO
Colombia
Prior art keywords
cov
sars
deoptimized
methods
coronavirus infection
Prior art date
Application number
CONC2022/0010743A
Other languages
English (en)
Inventor
Steffen Mueller
John Robert Coleman
Ying Wang
Chen Yang
Original Assignee
Codagenix Inc
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codagenix Inc, Serum Institute Of India Pvt Ltd filed Critical Codagenix Inc
Publication of CO2022010743A2 publication Critical patent/CO2022010743A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se proveen coronavirus SARS-CoV-2 modificados. Estos virus han sido recodificados, por ejemplo, mediante desoptimización de codones o desoptimización del sesgo de pares de codones y son de utilidad para reducir la probabilidad o severidad de una infección por coronavirus SARS-CoV-2, para prevenir una infección por coronavirus SARS-CoV-2, para generar una respuesta inmunológica o para tratar una infección por coronavirus SARS-CoV-2.
CONC2022/0010743A 2020-01-28 2022-07-29 Sars-cov-2 desoptimizados y métodos y usos de los mismos CO2022010743A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062966750P 2020-01-28 2020-01-28
US202063048942P 2020-07-07 2020-07-07
US202063079337P 2020-09-16 2020-09-16
US202063079853P 2020-09-17 2020-09-17
PCT/US2021/015246 WO2021154828A1 (en) 2020-01-28 2021-01-27 DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF

Publications (1)

Publication Number Publication Date
CO2022010743A2 true CO2022010743A2 (es) 2022-08-30

Family

ID=77078567

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0010743A CO2022010743A2 (es) 2020-01-28 2022-07-29 Sars-cov-2 desoptimizados y métodos y usos de los mismos

Country Status (15)

Country Link
US (1) US20230117167A1 (es)
EP (1) EP4096712A4 (es)
JP (1) JP2023519640A (es)
KR (1) KR20220132588A (es)
CN (1) CN115427073A (es)
AU (1) AU2021213121A1 (es)
BR (1) BR112022014700A2 (es)
CA (1) CA3168100A1 (es)
CL (1) CL2022002030A1 (es)
CO (1) CO2022010743A2 (es)
IL (1) IL295112A (es)
MX (1) MX2022009099A (es)
PE (1) PE20230166A1 (es)
TW (1) TW202144570A (es)
WO (1) WO2021154828A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US20230108926A1 (en) * 2020-02-07 2023-04-06 RNAimmune, Inc. COMPOSITION AND METHOD OF mRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION
CN115803463A (zh) * 2020-03-06 2023-03-14 基因特力株式会社 用于诊断SARS-CoV-2的组合物、试剂盒以及通过使用所述试剂盒诊断SARS-CoV-2的方法
WO2022011428A1 (en) * 2020-07-16 2022-01-20 Griffith University Live-attenuated virus vaccine
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
WO2023037387A2 (en) 2021-09-08 2023-03-16 Serum Institute Of India Private Limited Freeze-dried viral combination vaccine compositions and process for preparation thereof
WO2023138770A1 (en) * 2022-01-20 2023-07-27 Freie Universität Berlin A live attenuated sars-cov-2 and a vaccine made thereof
WO2023186946A1 (en) * 2022-03-28 2023-10-05 Universität Bern One-to-stop attenuated sars-cov-2 virus
WO2024052336A1 (en) 2022-09-05 2024-03-14 Freie Universität Berlin A live attenuated sars-cov-2 and a vaccine made thereof
EP4331602A1 (en) * 2022-09-05 2024-03-06 Freie Universität Berlin A live attenuated sars-cov-2 and a vaccine made thereof
WO2024079285A1 (en) * 2022-10-12 2024-04-18 Universität Bern Treatment using a one-to-stop attenuated sars-cov-2 virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
EP2808384B1 (en) * 2004-10-08 2017-12-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Modulation of replicative fitness by using less frequently used synonymous codons
EP3431099B1 (en) * 2007-03-30 2024-01-03 The Research Foundation for The State University of New York Attenuated viruses useful for vaccines

Also Published As

Publication number Publication date
JP2023519640A (ja) 2023-05-11
MX2022009099A (es) 2022-10-20
TW202144570A (zh) 2021-12-01
KR20220132588A (ko) 2022-09-30
PE20230166A1 (es) 2023-02-01
WO2021154828A1 (en) 2021-08-05
EP4096712A1 (en) 2022-12-07
AU2021213121A1 (en) 2022-08-18
CA3168100A1 (en) 2021-08-05
US20230117167A1 (en) 2023-04-20
CN115427073A (zh) 2022-12-02
EP4096712A4 (en) 2024-05-08
IL295112A (en) 2022-09-01
BR112022014700A2 (pt) 2022-10-11
CL2022002030A1 (es) 2023-03-10

Similar Documents

Publication Publication Date Title
CO2022010743A2 (es) Sars-cov-2 desoptimizados y métodos y usos de los mismos
UY37961A (es) Nuevas y altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)
EA202193251A1 (ru) Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций
EA201792429A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге
UY37962A (es) Nuevas y altamente activas indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
UY35266A (es) Compuestos antivirales
EA201791614A1 (ru) Производные индола в качестве ингибиторов репликации вирусов денге
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
EA201992334A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201992782A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
CL2015001971A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas.
UY36903A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
PE20171132A1 (es) Metodos mejorados para la inactivacion de enterovirus y la adsorcion sobre coadyuvantes, y composiciones de vacunas con dosis reducidas obtenidas de estos
CL2021002807A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
WO2020055858A8 (en) Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
BR112021025655A2 (pt) Inibidores da replicação do vírus da imunodeficiência humana
AR121148A1 (es) SARS-CoV-2 DESOPTIMIZADOS Y MÉTODOS Y USOS DE LOS MISMOS
EA201891555A1 (ru) Вирус вакцины от репродуктивно-респираторного синдрома свиней
CL2022002396A1 (es) Compuestos para su uso en infecciones víricas
EA201892830A1 (ru) Применение ксиборнола в качестве активного агента для лечения вирусных инфекций